How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years

How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years

ObjectiveWe aimed to study the epidemiology of the prodromal and mild stages of Alzheimer’s disease (AD) patients who are eligible for clinical trials with disease-modifying therapies.SettingsWe analysed two large complementary databases to study the incidence and characteristics of this population...

Full description

Bibliographic Details
Main Authors: Didier Hannequin, Florence Pasquier, Bruno Dubois, David Wallon, Julien Dumurgier, Stéphane Epelbaum, Thérèse Jonveaux, Annick Besozzi, Stéphane Pouponneau, Caroline Hommet, Laetitia Berly, Adrien Julian, Marc Paccalin, Julie Bellet, Claire Boutoleau-Bretonniere, Thiphaine Charriau, Olivier Rouaud, Olivier Madec, Aurélie Mouton, Renaud David, Samir Bekadar, Roxane Fabre, Walter Deberdt
Format: Article
Language:English
Published: BMJ Publishing Group 2019-06-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/9/6/e029663.full

Internet

https://bmjopen.bmj.com/content/9/6/e029663.full

Similar Items